Atara Biotherapeutics Inc
Change company Symbol lookup
Select an option...
ATRA Atara Biotherapeutics Inc
GATX GATX Corp
UAL United Airlines Holdings Inc
TEL TE Connectivity Ltd
HPGN HypGen Inc
IX Orix Corp
WHR Whirlpool Corp
PG Procter & Gamble Co
PWJAX PGIM Jennison International Opportunities Fund- Class A
MBWM Mercantile Bank Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Price
Delayed
$13.22
Day's Change
-0.07 (-0.53%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.23
Day's Low
12.84
Volume
(Light)

Today's volume of 32,639 shares is on pace to be much lighter than ATRA's 10-day average volume of 927,839 shares.

32,639

Should you invest in Nio, General Electric, Bank of America, Li Auto, or CBS Corp?

11:20 am ET March 9, 2021 (PR Newswire) Print

InvestorsObserver issues critical PriceWatch Alerts for NIO, GE, BAC, LI, and VIAC.

https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report - Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report - Measures a stock's suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street's opinion including a 12-month price forecast.

-- NIO: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=NIO&prnumber=030920216

-- GE: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=GE&prnumber=030920216

-- BAC: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=BAC&prnumber=030920216

-- LI: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=LI&prnumber=030920216

-- VIAC: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=VIAC&prnumber=030920216

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

https://c212.net/c/img/favicon.png?sn=CG03856&sd=2021-03-09

View original content to download multimedia:http://www.prnewswire.com/news-releases/should-you-invest-in-nio-general-electric-bank-of-america-li-auto-or-cbs-corp-301243621.html

SOURCE InvestorsObserver

https://rt.prnewswire.com/rt.gif?NewsItemId=CG03856&Transmission_Id=202103091120PR_NEWS_USPR_____CG03856&DateId=20210309

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.